Roivant Sciences Ltd. (NASDAQ:ROIV) COO Sells $2,050,704.16 in Stock

Roivant Sciences Ltd. (NASDAQ:ROIV) COO Eric Venker sold 177,704 shares of the stock in a transaction on Monday, December 30th. The shares were sold at an average price of $11.54, for a total value of $2,050,704.16. Following the transaction, the chief operating officer now directly owns 740,976 shares of the company’s stock, valued at approximately $8,550,863.04. This trade represents a 19.34 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.

Eric Venker also recently made the following trade(s):

• On Friday, December 27th, Eric Venker sold 176,900 shares of Roivant Sciences stock. The shares were sold at an average price of $11.82, for a total value of $2,090,958.00.
• On Friday, December 20th, Eric Venker sold 100,000 shares of Roivant Sciences stock. The stock was sold at an average price of $11.49, for a total transaction of $1,149,000.00.
• On Wednesday, November 20th, Eric Venker sold 100,000 shares of Roivant Sciences stock. The shares were sold at an average price of $11.32, for a total transaction of $1,132,000.00.
• On Monday, October 21st, Eric Venker sold 100,000 shares of Roivant Sciences stock. The stock was sold at an average price of $11.65, for a total transaction of $1,165,000.00.

Roivant Sciences Stock Up 3.5 %

NASDAQ:ROIV traded up $0.40 during midday trading on Tuesday, hitting $11.83. The company had a trading volume of 4,205,813 shares, compared to its average volume of 5,754,317. The company has a market capitalization of $8.61 billion, a PE ratio of 2.09 and a beta of 1.25. Roivant Sciences Ltd. has a 52-week low of $9.69 and a 52-week high of $13.06. The stock’s fifty day moving average price is $11.91 and its 200-day moving average price is $11.55.

Hedge Funds Weigh In On Roivant Sciences

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Bank of New York Mellon Corp lifted its position in Roivant Sciences by 2.2% in the 2nd quarter. Bank of New York Mellon Corp now owns 2,686,538 shares of the company’s stock worth $28,397,000 after buying an additional 58,541 shares during the last quarter. Allspring Global Investments Holdings LLC boosted its stake in shares of Roivant Sciences by 85.5% in the 2nd quarter. Allspring Global Investments Holdings LLC now owns 130,631 shares of the company’s stock valued at $1,381,000 after purchasing an additional 60,221 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in Roivant Sciences by 27.8% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 79,287 shares of the company’s stock worth $838,000 after purchasing an additional 17,248 shares during the period. Crossmark Global Holdings Inc. purchased a new stake in shares of Roivant Sciences during the second quarter valued at approximately $218,000. Finally, nVerses Capital LLC bought a new position in shares of Roivant Sciences in the second quarter worth approximately $34,000. 64.76% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several research firms have issued reports on ROIV. Cantor Fitzgerald restated an “overweight” rating on shares of Roivant Sciences in a research report on Thursday, September 19th. Bank of America upped their price target on Roivant Sciences from $12.00 to $12.50 and gave the company a “neutral” rating in a research report on Wednesday, September 11th. Finally, HC Wainwright reissued a “buy” rating and issued a $18.00 price target on shares of Roivant Sciences in a report on Wednesday, November 13th. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $17.93.

Roivant Sciences Company Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.